ArticleFrontiers in pharmacology2025
BaDuShengJi hydrogel accelerates diabetic wounds healing and regeneration of deep burn injury by anti-bacteria, anti-inflammation and promoting epithelialization.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated multi-technology exploration of the mechanism by which Badushengji San regulates core targets in diabetic foot ulcer.Molecular genetics and genomics : MGG · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial infection, excessive inflammation, and delayed re-epithelialization are the biggest obstacles to diabetic wound healing and burn injuries. As a classic prescription, BaDuShengJi San (BDS) has been proven to accelerate chronic wound healing through anti-bacterial and anti-inflammatory mechanisms. However, there are few reports on its role in preventing the malignant progression of deep burns or accelerating deep burn wound healing. Furthermore, the powder formulation of BDS has limited application scenarios, difficult dosage control, potential environmental pollution, and contradiction with the theory of moist wound healing, which has constrained its scope of application and efficacy to some extent. To address these issues, this study developed a novel hydrogel formulation incorporating BDS using carbomer 940 as the gel matrix, glycerol as a humectant, and triethanolamine as a pH adjuster, through orthogonal design. The results demonstrated that the prepared BDS-loaded gel (BDN) exhibited excellent stability and good biocompatibility, preserving the antibacterial and angiogenesis-promoting properties of BDS while enhancing its anti-inflammatory capabilities. Additionally, BDN significantly accelerated re-epithelialization in diabetic chronic wounds and burn wounds compared to BDS, achieving superior healing quality and mitigating renal damage associated with long-term BDS application. This study provides a comprehensive strategy for accelerating wound healing in diabetic chronic wounds and deep burn injuries and offers insights into expanding the clinical application of BDS and enhancing its therapeutic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.